

# 1 Preimmunization correlates of protection 2 shared across malaria vaccine trials in adults

3  
4 Maxwell L. Neal<sup>1</sup>, Fergal J. Duffy<sup>1</sup>, Ying Du<sup>1</sup>, John D. Aitchison<sup>1,2,3\*</sup>, Kenneth D. Stuart<sup>1,4,5\*</sup>

5 <sup>1</sup> Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA,  
6 United States

7 <sup>2</sup> Department of Pediatrics, University of Washington, Seattle, WA, United States

8 <sup>3</sup> Department of Biochemistry, University of Washington, Seattle, WA, United States

9 <sup>4</sup> Department of Global Health, University of Washington, Seattle, WA, United States

10 <sup>5</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United  
11 States

12

13

14 \* Co-corresponding authors

15

16 [John.Aitchison@seattlechildrens.org](mailto:John.Aitchison@seattlechildrens.org)

17 [Ken.Stuart@seattlechildrens.org](mailto:Ken.Stuart@seattlechildrens.org)

## 18 Abstract

19 Identifying preimmunization biological characteristics that promote an effective vaccine  
20 response offers opportunities for illuminating the critical immunological mechanisms that confer  
21 vaccine-induced protection, for developing adjuvant strategies, and for tailoring vaccination  
22 regimens to individuals or groups. In the context of malaria vaccine research, studying  
23 preimmunization correlates of protection can help address the need for a widely-effective  
24 malaria vaccine, which remains elusive. In this study, common preimmunization correlates of  
25 protection were identified using transcriptomic data from four independent, heterogeneous  
26 malaria vaccine trials in adults. Systems-based analyses showed that a moderately elevated  
27 inflammatory state prior to immunization was associated with protection against malaria  
28 challenge. Functional profiling of protection-associated genes revealed the importance of  
29 several inflammatory pathways, including TLR signaling. These findings, which echo previous  
30 studies that associated enhanced preimmunization inflammation with protection, illuminate  
31 common baseline characteristics that set the stage for an effective vaccine response across  
32 diverse malaria vaccine strategies in adults.

## 33 Introduction

34 Whether a vaccine generates an immune response that results in protection from infection or  
35 disease depends in part on the preimmunization status and capacities of the vaccinated  
36 individual's immune system<sup>1</sup>. Identifying preimmunization correlates of protection, therefore,  
37 offers opportunities for illuminating the immunological pathways that promote or attenuate  
38 protective vaccine responses, for identifying avenues whereby the immune system can be  
39 influenced to respond effectively, and for developing personalized approaches that predict  
40 vaccine efficacy on an individual or group basis. These opportunities can potentially benefit  
41 malaria vaccine development efforts: Although substantial progress has been made developing  
42 anti-malaria vaccines, a vaccine that is widely-effective has remained elusive<sup>2-5</sup>, and it remains  
43 unclear why malaria vaccines induce a protective response in some individuals but not in  
44 others. Exploring the preimmunization correlates of protection in malaria vaccine trials presents  
45 an opportunity to identify the immunological conditions that set the stage for vaccine-induced  
46 responses that are protective against future infection and to help guide the rational design of  
47 more effective vaccines. While the list of studies in this research area is not extensive, some  
48 preimmunization correlates of protection have been identified for vaccines against influenza<sup>6-9</sup>,  
49 hepatitis B<sup>10-12</sup>, yellow fever<sup>13</sup> and malaria<sup>14-21</sup>.

50  
51 To identify common preimmunization correlates of protection across various malaria vaccine  
52 trials, we performed transcriptomic analysis of four independent trials: the Immunization via  
53 Mosquito Bite with Radiation-Attenuated *P. falciparum* Sporozoites (IMRAS) trial<sup>22</sup>, the  
54 Bagamoyo SPorozoite Vaccination 1 (BSPZV1) trial<sup>23</sup>, the MAL68 RTS,S vaccine trial<sup>24</sup>, and a  
55 Chloroquine Prophylaxis and Sporozoites (CPS) trial<sup>25,26</sup>. These trials varied in the vaccines  
56 administered (live, radiation-attenuated whole sporozoites, RTS,S subunit vaccine or live  
57 sporozoites where establishment of blood stage infection was prevented by chloroquine  
58 chemoprophylaxis), the route of administration (intravascular injection, intramuscular injection,  
59 or mosquito bite) the country of trial subject recruitment (USA, Tanzania, or The Netherlands),  
60 whether subjects were malaria-naïve prior to immunization (USA, The Netherlands) or  
61 experienced (Tanzania), and the source of transcriptomic material (whole blood or peripheral  
62 blood mononuclear cells - PBMCs). Each trial included a challenge phase, wherein subjects  
63 were infected with infectious *P. falciparum* to determine whether the subject mounted a vaccine  
64 response protective against malaria. To our knowledge, this study is the first to investigate  
65 preimmunization correlates of protection from transcriptomics across multiple, heterogenous  
66 malaria vaccine trials in adults. Despite the wide-ranging clinical trial conditions, our results  
67 indicate that protection against post-immunization malaria challenge is associated with innate  
68 immune system activation and a moderately elevated inflammatory state prior to immunization,  
69 including higher expression in genes associated with TLR signaling and other inflammatory  
70 pathways. These results echo molecular- and pathway-level preimmunization correlates of  
71 malaria protection derived from previous analyses on narrower sets of clinical trials<sup>19,21</sup>. They  
72 highlight specific immunological pathways that may play critical roles in the development of  
73 effective malaria vaccine-elicited responses and offer potential targets for manipulating the  
74 immune system into a state that promotes such responses.

## 75 Results


### 76 Correlates of protection among pooled preimmunization 77 transcriptomes

78 Preimmunization transcriptomes were pooled from the four malaria vaccine trials and consisted  
79 of 84 samples (Table 1, Methods). A differential expression analysis comparing the  
80 transcriptomes of all protected participants ( $n=38$ ) and all non-protected participants ( $n=46$ )  
81 pooled from the trials revealed no genes with statistically-significant differences in transcript  
82 abundance using an FDR-adjusted  $P$ -value cutoff of 0.1. To test for differences among  
83 functionally-related *groups* of genes, we performed Gene Set Enrichment Analysis (GSEA)<sup>27</sup> to  
84 identify statistically-significant overrepresentation of predefined gene sets including  
85 immunological blood transcriptional modules<sup>28,29</sup> and the MSigDB Hallmark gene sets<sup>30</sup>. GSEA  
86 results on genes ranked according to their DESeq2 Wald test statistic revealed significant  
87 differences in transcript abundances (FDR-adjusted  $P$ -value < 0.05) among 207 gene sets.  
88 Gene sets enriched for higher abundance transcripts in protected subjects were predominantly  
89 associated with inflammation and inflammatory signaling pathways, myeloid lineage cells  
90 including monocytes and neutrophils, coagulation, antigen presentation, cell death and  
91 apoptosis, the endoplasmic reticulum, the extracellular matrix, and the complement system (Fig.  
92 1). Gene sets enriched for lower abundance transcripts in protected subjects were  
93 predominantly associated with the cell cycle, protein synthesis, interferon, T cells, mitochondria  
94 stress/respiration, and NK cells. As illustrated in Fig. 2, leading-edge genes (those primarily  
95 responsible for the significant enrichment scores due to non-random grouping at the tails of a  
96 ranked list) from gene sets with the highest and lowest normalized enrichment scores (NESs)  
97 showed moderate differences in transcript abundance between protected and non-protected  
98 subjects. For example, the top 10 leading-edge genes in Fig. 2a showed a mean  $\log_2$  fold-  
99 change of  $0.41 \pm 0.22$  (SD) between protected and non-protected subjects. Our analysis  
100 revealed that, when comparing protected and non-protected subjects, differences in transcript  
101 abundance of gene *sets* showed statistical significance, whereas differences at the individual  
102 gene level did not.

**Table 1. Characteristics of the four clinical trials that generated transcriptomic data used to identify preimmunization correlates of protection.**


Trial name (ClinicalTrials.gov ID)	Immunogen	Recruitment country	Sample source	$N$ preimmunization samples	Prior malaria exposure	$N$ female / male	$N$ challenge- protected / non-protected
IMRAS <i>Immunization via Mosquito Bite with Radiation-Attenuated P. falciparum Sporozoites</i> (NCT01994525)	Radiation-attenuated sporozoites via mosquito bite	U.S.A.	Whole blood	11	Naïve	1 / 10	6 / 5
BSPZV1 <i>Bagamoyo Sporozoite Vaccination 1</i> (NCT02132299)	Radiation-attenuated sporozoites via IV injection	Tanzania	Whole blood	22	Non-naïve	0 / 22	8 / 14
MAL68 (NCT01366534)	RTS,S/A01 ± Ad35.CS.01 vaccine via injection	U.S.A.	PBMCs	45	Naïve	20 / 25	21 / 24
CPS <i>Chloroquine Prophylaxis and Sporozoites</i> (NCT01218893)	Sporozoites via mosquito bite (under chloroquine cover)	The Netherlands	Whole blood	7	Naïve	3 / 4	3 / 4

103




**Figure 1. GSEA results on the pooled set of preimmunization transcriptomes from four malaria vaccine trials.** Gene sets with positive GSEA normalized enrichment scores indicate they are significantly enriched for genes with higher transcript abundance in protected subjects; negative scores indicate significant enrichment for genes with lower transcript abundance in protected subjects. Gene sets shown have absolute scores > 2.0 and FDR-adjusted *P*-values < 0.05. Sets named “Undetermined” or “TBA” are not shown.

## a DC.M3.2 Inflammation



## b LI.M4.1 cell cycle (l)




**Figure 2. Violin plots comparing transcript abundance of GSEA-derived leading-edge genes in protected (P) and non-protected (NP) subjects pooled from four malaria vaccine trials. a** Transcript abundance in counts per million (CPM) for the top ten leading-edge genes in *DC.M3.2 Inflammation*, the gene set showing the highest significant normalized enrichment score in the GSEA analysis (indicating significantly higher abundances in protected subjects). **b** Transcript abundance for the top ten leading-edge genes in *LI.M4.1 cell cycle (l)*, the gene set showing the lowest significant normalized enrichment score in the analysis (indicating significantly lower abundances in protected subjects).

## 126 Correlates of protection shared across individual trials

127 The analyses on the pooled set of preimmunization transcriptomes includes all samples  
128 aggregated across all four trials. To perform a more conservative analysis that limits correlates  
129 driven primarily by individual trials, we computed differential expression and performed GSEA  
130 for each trial separately, then identified genes and gene sets that consistently showed  
131 significant differences between protected and non-protected subjects across trials. As with the  
132 differential expression analysis on the pooled transcriptomes, the number of transcripts showing  
133 significant differences in abundance between protected and non-protected subjects was low in  
134 each trial ( $N = 2$  for IMRAS,  $N = 0$  for BSPZV1 and MAL68,  $N = 14$  for CPS; FDR-adjusted  $P$ -  
135 value  $< 0.1$ ). To identify differences at the level of gene sets, we then performed the same type  
136 of GSEA as performed with the pooled samples. From the GSEA results on each trial, we then  
137 identified gene sets that showed significant positive enrichment scores consistently across all  
138 trials or consistently showed significant negative scores. Fourteen gene sets showed  
139 directionally-consistent, significant enrichment for genes with higher expression in protected  
140 subjects across trials, and two sets showed directionally-consistent, significant enrichment for  
141 genes with lower expression in protected subjects across trials (Fig. 3).

142  
143 The 14 gene sets showing consistently higher transcript levels in protected subjects prior to  
144 immunization were predominantly associated with inflammatory responses, monocytes, and  
145 neutrophils. The two gene sets showing consistently lower transcript levels in protected subjects  
146 were associated with the cell cycle and protein synthesis. To determine the probability of seeing  
147 16 gene sets significantly enriched across all four trials with consistent directionality in their




**Figure 3. Heatmap of GSEA normalized enrichment scores for gene sets showing directionally-consistent, significant enrichment for gene transcripts with higher abundance in protected subjects across malaria vaccine trials or lower abundance across trials.**

148 enrichment scores by chance, we randomly assigned protected/non-protected status to each  
149 trial subject, re-computed differential expression between protected and non-protected subjects,  
150 performed GSEA on the ranked DESeq2 results, and then recorded the number of gene sets  
151 showing directionally-consistent, significant enrichment in all four trials. This was done in a  
152 manner that preserved the original number of protected and non-protected subjects in each trial.  
153 We performed 10,000 iterations of this procedure, each of which used a unique set of protection  
154 assignments and found that the probability of seeing 16 or more directionally-consistent,  
155 significantly-enriched gene sets appear in all four trials was less than 0.007.

## 156 Pathway analysis of leading-edge genes common across trials


157 While the gene sets used in our GSEA analysis are useful for characterizing gene groups  
158 according to their more general biological functions, they do not represent specific mechanistic  
159 molecular pathways. To identify such pathways that were consistently associated with  
160 protection at the preimmunization timepoint, we performed an Ingenuity Pathway Analysis  
161 (IPA)<sup>31</sup> on the set of common leading-edge genes collected from the gene sets in Fig. 3 that  
162 showed directionally-consistent, significant enrichment across vaccine trials. For each of these  
163 16 functional gene sets, we collected the genes that appeared as GSEA leading-edge genes for  
164 that set in all four trials. Across these 16 gene sets, we found 98 such genes (Supplementary

165 Table S1). Functionally profiling these genes collectively with IPA yielded significant enrichment  
 166 (Fisher's exact test, FDR-adjusted  $P$ -value < 0.05) for 28 IPA Canonical Pathways (Fig. 4).  
 167 Reflecting the GSEA results, the 28 pathways were primarily associated with inflammation,  
 168 including many pathways in which Toll-like receptors (TLRs) and MYD88 participate. For each  
 169 of the 98 genes input to IPA for this analysis, we computed the mean  $\log_2$  fold-change  
 170 differences in transcript abundance between protected and non-protected subjects across trials,  
 171 and these values were used by IPA to identify which of the 28 Canonical Pathways showed a  
 172 consistent activation or inactivation profile. The Canonical Pathway with the highest enrichment  
 173 score that also showed a consistent activation or inactivation profile was the Toll-like Receptor  
 174 Signaling pathway. Fig. 5 shows the IPA diagram for this pathway, highlighting the overlap  
 175 between members of the 98-gene list and the pathway's molecular participants as well as the  
 176 mean abundance differences of those overlapping participants when comparing protected to  
 177 non-protected trial subjects.  
 178



**Figure 4. IPA Canonical Pathways analysis on common leading-edge genes from gene sets that showed directionally-consistent, significant GSEA enrichment scores across trials.** Bar width indicates the strength of an IPA Canonical Pathway's enrichment for the leading-edge genes. Bar color indicates the IPA z-score, which is the degree to which the pathway is activated (orange) or inactivated (blue) based on mean  $\log_2$  fold-changes in transcript abundance between protected and non-protected subjects for leading-edge genes found in the pathway. White bars indicate an ambiguous activation state ( $z = 0$ ) or pathways ineligible for activation analysis because the overlap between common leading-edge genes and pathway participants used to compute the z-score was less than four ( $z\text{-score} = \text{NaN}$ ). Gray bars indicate that there is insufficient evidence in the IPA Knowledge Base to confidently predict an activation state for the pathway.






**Figure 5. IPA network diagram of the Toll-like Receptor Signaling pathway, illustrating higher preimmunization activity in protected subjects.** The pathway shows enrichment for six protection-associated leading-edge gene transcripts found across vaccine trials, indicated by icons with red borders. Icon fill color indicates the  $\log_2$  fold-changes in transcript abundance when comparing protected to non-protected subjects, averaged across the four vaccine trials.

179 In addition to the Canonical Pathways analysis, we also performed an IPA Upstream Analysis,  
 180 which provides hypotheses about which molecular perturbations might cause the expression  
 181 differences observed in the 98-gene list. In the context of this study, this analysis can help  
 182 identify pathway activators and inactivators (naturally-occurring or synthetic) with the potential to  
 183 shift an individual's immunological state in the direction that is more consistent with a protective  
 184 response to immunization. The molecules with high IPA activation z-scores ( $\geq 2.0$ ) showing  
 185 significant FDR-adjusted *P*-values in this analysis included cytokines with proinflammatory  
 186 activity (type I and type II interferons, IL1B, TNF, IL17A, IL33, IL18, IL6, IL12, IL1A, IL5),  
 187 cytokine groups (IL12, IL1), lipopolysaccharides, colony stimulating factors (CSF2 and the  
 188 pharmaceutical analog of CSF3 filgrastim), transcription regulators (the NFκB complex, CEBPA,

189 SPI1, TCF7L2, STAT3, RELA, IRF7), Toll-like receptors (TLR2, TLR4) as well as adapter  
190 proteins that participate in their signaling pathways (TICAM1, MYD88), other immunomodulators  
191 (tretinoin, ethanol, SPI1, TGM2, poly rI:rC-RNA, mycophenolic acid, POU2F2, KITLG), the  
192 protein synthesis regulator LARP1, thrombin, APP, signaling pathway enzymes and ligands  
193 (PARP1, PI3K, KITLG, the p38 MAPK group), the PDGF-BB complex, the growth hormone  
194 protein group, the C11orf95-RELA gene fusion product, and ZBTB10. Based on the IPA  
195 knowledge base, increased activity of these molecules would shift expression of the 98 leading-  
196 edge genes in a manner consistent with their mean expression differences between protected  
197 and non-protected subjects across trials. The upstream molecules with low IPA activation z-  
198 scores ( $\leq -2.0$ ) showing significance included the p38 MAPK inhibitor SB203580, the  
199 progesterone antagonist mifepristone, miR-155-5p, the alpha catenin protein group, the  
200 transcription factor MLXIPL, the transcription inhibitor actinomycin D, DIO3 and DUSP1, the  
201 gene fusion product ETV6-RUNX1, the immunosuppressant cyclosporin A, and the  
202 corticosteroid budesonide. Decreased activity of these molecules is predicted to induce  
203 expression changes in the 98 leading-edge genes consistent with those observed between  
204 protected and non-protected subjects. The full set of Upstream Analysis results are provided in  
205 Supplementary Table S2.

## 206 Discriminatory power of protection-associated genes and gene sets

207 The protection-associated genes and gene sets common across trials suggest there are  
208 transcriptomic features that might be used in classifiers that discriminate, on an individual basis,  
209 which vaccinees will mount a protective immune response to immunization and which will not.  
210 To assess the discriminatory power of these features, we developed and tested various scores  
211 based on transcript abundances (counts per million) of the 98 protection-associated, leading-  
212 edge genes described above as well as mean transcript levels corresponding to those genes  
213 within protection-associated gene sets. We also tested the discriminatory power of scores  
214 based on transcript abundance *ratios* between protection-associated genes and between gene  
215 sets. For all scoring strategies, individual scores were computed for each trial participant based  
216 on their preimmunization transcriptomic profile. We then assessed the discriminatory power of  
217 the score by varying the threshold used to classify individuals as protected or non-protected and  
218 then generating a receiver operating characteristic (ROC) curve from the sensitivity and  
219 specificity of the classifiers. We quantified the discriminatory power of each score based on the  
220 area under the curve (AUC) of the ROC results. We found that the ratio of mean leading-edge  
221 gene expression in the *HALLMARK TNFA SIGNALING VIA NFKB* gene set to that of the  
222 *DC.M4.3 Protein synthesis* gene set produced a score with the highest discriminatory power  
223 (AUC = 0.73, 95% confidence interval 0.61-0.84, Fig. 6a). A Mann-Whitney U test showed that  
224 this score was significantly different between the protected and non-protected subjects pooled  
225 from all four trials (FDR-adjusted *P*-value = 0.034, Fig. 6b). The score incorporates expression  
226 information from eight members of the *HALLMARK TNFA SIGNALING VIA NFKB* gene set  
227 (BCL3, BTG1, CCRL2, CEBPD, CXCL1, PFKFB3, PTGS2, SLC2A3) and seven from the  
228 *DC.M4.3 Protein synthesis* set (RPL4, RPL5, RPL6, RPS3, RPS14, RPS18, TOMM7).



**Figure 6. Discriminatory power of the best-performing preimmunization score for classifying protected and non-protected trial subjects.** **a** Receiver operating characteristic (ROC) curve showing performance of the score across 84 subjects pooled across trials. **b** Boxplots showing score distributions among subjects who were protected (P) following malaria challenge and those who were not (NP). **c** ROC curves showing performance of the score within each individual trial. (AUC: area under the curve; CI: confidence interval).

229

230 To test whether the discriminatory power of the best-performing score might be biased by  
231 specific trials in our study, we computed separate ROC curves for each trial using only their  
232 participating subjects and their corresponding scores. We found that the score showed  
233 comparable discriminatory power across trials (Fig. 6c). The score's performance was poorest  
234 in the BSPZV1 cohort (AUC=0.64, 95% confidence interval 0.36-0.93) and highest in the CPS  
235 cohort where it perfectly discriminated between protected and non-protected subjects.

## 236 Discussion

237 Our findings indicate that a moderately elevated preimmunization inflammatory state, as  
238 revealed by RNA-seq transcriptomic measurements on whole blood or PBMCs, is associated  
239 with a protective response to malaria challenge following a variety of immunization strategies in  
240 adults. A heightened preimmunization inflammatory state has previously been linked to vaccine-  
241 induced protection against influenza in non-elderly adults<sup>6</sup>, and our results also link this finding  
242 to the malaria vaccination strategies analyzed here. Our findings contrast with studies  
243 investigating correlates of protection following hepatitis B immunization where innate immune  
244 activation prior to immunization has been linked to non-protection in adults<sup>10-12</sup>.

245  
246 Across the four trials we analyzed, transcripts from several inflammatory and innate response  
247 gene sets trended higher in protected subjects, and this trend was significant when treating  
248 gene sets as the unit of analysis. Analyses at the level of individual transcripts did not reveal  
249 significant differences between protected and non-protected subjects across trials. Thus, the  
250 expression differences we observed between these groups link protection to a moderately  
251 higher activation of inflammatory and innate response processes. While moderate, these  
252 differences are substantial enough to have potential utility in metrics that predict whether an  
253 individual subject will mount a protective vaccine response prior to immunization (Fig. 6). In  
254 future work, metrics based on the discriminatory transcriptomic features identified here might be  
255 combined with other protection-associated preimmunization measurements (e.g., cell type  
256 abundances) to create robust, accurate classifiers suitable for identifying individuals at risk for a  
257 poor vaccine response in a clinical setting.

258  
259 The set of common leading-edge genes gathered from our GSEA results showed enrichment for  
260 more fine-grained signaling pathways, most of which included TLR4 as a participant. These  
261 results echo previous findings by Moncunill, et al.<sup>19</sup> who identified TLR4 as a member of several  
262 gene signatures predictive of protection in RTS,S-vaccinated children. These signatures were  
263 derived from expression changes in preimmunization PBMCs that were stimulated with CSP  
264 and/or *P. falciparum*-infected erythrocytes. Their results suggested that higher preimmunization  
265 TLR4 expression may help the immune system respond more effectively to the RTS,S vaccine.  
266 As noted by these authors, the LPS-derived chemical monophosphoryl lipid A (MPL) used as an  
267 adjuvant in combination with the subunit RTS,S vaccine is a TLR4 agonist<sup>19,32,33</sup>. Our results,  
268 which link higher preimmunization expression of TLR1, TLR4 and TLR8 to protection, also  
269 suggest a role for TLR agonists as adjuvants in the development of a protective vaccine  
270 response.

271  
272 Moncunill, et al. also found preimmunization signatures of protection in a separate trial where  
273 adults were immunized with fresh sporozoites delivered via mosquito bite under chloroquine  
274 prophylaxis. The best performing preimmunization signature derived from CSP-stimulated  
275 PBMCs for this trial linked protection with proinflammatory activity of participants in the  
276 canonical and non-canonical NFκB pathways. These pathway participants included CSF2 (also  
277 known as GM-CSF), and our IPA Upstream Analysis identified CSF2, RELA, and NFκB complex  
278 activation as potential upstream perturbations contributing to the increased expression and

279 transcript abundance differences we observed between protected and non-protected subjects.  
280 Also included in the CPS signature is ITGA2, an integrin that contributes to p38 MAPK signaling  
281 which in turn controls the activity of the RELA NFκB subunit. The p38 MAPK signaling pathway  
282 was also enriched for leading-edge genes associated with protection across trials in our IPA  
283 Canonical Pathways analysis (Fig. 4). The leading-edge genes participating in this pathway  
284 included CREB5, IL18RAP, IL1RN and IRAK3, all of which showed elevated expression in  
285 protected subjects across trials. These results suggest that, although we did not see overlap  
286 between our set of 98 leading-edge genes and the genes in the preimmunization signature  
287 associated with CSP-stimulation in the chloroquine prophylaxis trial analyzed by Moncunill, et  
288 al., NFκB-mediated inflammation pathways appear to be a critical determinant of protection in  
289 both studies.

290  
291 An important difference between the Moncunill, et al. study and ours is that our transcriptomic  
292 measurements were taken from unstimulated tissues and therefore present snapshots of  
293 subjects' preimmunization immunological *states* whereas the Moncunill, et al. measurements  
294 reflect immunological *responses* to antigen stimulation. Taken together, these results associate  
295 protection with an innate immune system that is simultaneously more activated prior to  
296 immunization and more capable of responding to immunization. These results may be driven by  
297 higher-than-average innate immune functionality in protected subjects or lower-than-average  
298 functionality in non-protected subjects, or a combination of both. A recent report by Yap, et al.<sup>21</sup>  
299 provides evidence suggesting preimmunization correlates of protection may be driven by  
300 actively decreased inflammatory functions in non-protected subjects. The authors report that  
301 higher baseline expression of T cell inhibitory ligands CTLA-4 and TIM-3 in CD4<sup>+</sup> T cells is  
302 associated with a "slow-responder" phenotype in adults that is less likely to result in sterile  
303 protection following immunization via controlled human malaria infection under chloroquine  
304 prophylaxis (CHMI-CPS). Increases in these inhibitory ligands can result from mechanisms that  
305 protect against inflammation-induced damage (for example in response to chronic parasitemia  
306 in malaria-endemic areas). The authors argue that these inhibitory ligands may interfere with  
307 NFκB signaling, which is preferentially activated in subjects who mount a protective response to  
308 this type of immunization, and this leads to insufficient production of IFN-γ. Rapid induction of  
309 IFN-γ following immunization is a characteristic of a "fast-responder" phenotype in CHMI-CPS  
310 trials that is more likely to result in sterile protection. Consistent with these findings, our IPA  
311 Upstream Analysis identified increased IFN-γ as a perturbation that would generate expression  
312 changes consistent with those observed between protected and non-protected individuals. IFN-γ  
313 had the highest z-score in this analysis, indicating strong agreement between a hypothetical  
314 increase in IFN-γ and our observed expression patterns showing higher inflammation in  
315 protected subjects prior to immunization. Given this consistency between our findings and those  
316 of Yap, et al., it may be that non-protected individuals in our study had a less successful  
317 immunization response due to protective inflammatory inhibition. However, the group of  
318 individuals we analyzed was heterogeneous; therefore, we cannot rule out attributing protection  
319 to higher-than-average innate responses among protected subjects. Furthermore, these two  
320 interpretations are not mutually exclusive: our results may simultaneously reflect immuno-  
321 suppressive factors in non-protected subjects and immuno-activating factors in protected  
322 subjects.

323  
324 The results presented here suggest that assessing malaria vaccinee's preimmunization status  
325 may lead to important correlates of protection and tailoring immunization regimes accordingly  
326 may emerge as an important element to ensuring a protective response to immunization.  
327 Moreover, our results also offer potential pharmacological interventions that may coax an  
328 individual's immune state into one that is primed to respond effectively to immunization.

## 329 Methods

### 330 Transcriptomic data sources

331 Transcriptomic data were aggregated from adult participants in four malaria vaccine trials that  
332 included RNA-seq measurements at preimmunization timepoints and an assessment of  
333 protection against infectious *P. falciparum* following immunization. The trials, described below,  
334 are summarized in Table 1. Each trial investigated a different malaria vaccine candidate and,  
335 together, represent cohorts from malaria-naïve and non-naïve populations. From these trials, 85  
336 preimmunization transcriptomic profiles were available to investigate correlates of protection.

#### 337 Trial 1: IMRAS

338 The IMRAS trial<sup>22</sup> (ClinicalTrials.gov identifier NCT01994525:  
339 <https://clinicaltrials.gov/ct2/show/NCT01994525>) was performed in malaria-naïve participants  
340 recruited from the United States. The trial assessed the safety, tolerability, and biomarkers of  
341 protection of immunization via radiation-attenuated sporozoites delivered by infectious mosquito  
342 bites. Preimmunization transcriptomics data were obtained from whole blood samples collected  
343 on the day of the first immunization from 11 immunized participants in the trial's Cohort 1, each  
344 of whom received five doses of radiation-attenuated *P. falciparum* via mosquito bite. Three  
345 weeks after the fifth immunization, participants were challenged via *P. falciparum*-infected  
346 mosquito bites. To facilitate the identification of correlates of protection, the IMRAS  
347 immunization regimen was designed to achieve approximately 50% sterile protection in  
348 immunized participants: 6 out of the 11 immunized participants (54%) in Cohort 1 were  
349 protected following challenge.

#### 350 Trial 2: BSPZV1

351 The BSPZV1 trial<sup>23</sup> (ClinicalTrials.gov identifier NCT02132299:  
352 <https://clinicaltrials.gov/ct2/show/NCT02132299>) was performed in male, malaria-exposed  
353 recruits from Tanzania. The trial was designed to determine if protective immune responses  
354 against *P. falciparum* infection could be generated in a relatively non-immune population within  
355 a malaria-endemic country through immunization with aseptic, cryopreserved, live, radiation-  
356 attenuated *P. falciparum* sporozoites delivered intravenously (IV). Preimmunization  
357 transcriptomic data from 22 immunized participants were obtained from whole blood samples  
358 collected on the day of the first immunization. Each participant received five immunizations and,

359 three weeks after the last, were challenged with infectious, aseptic, cryopreserved *P. falciparum*  
360 sporozoites delivered IV.

### 361 Trial 3: MAL68

362 The MAL68 trial<sup>24</sup> (ClinicalTrials.gov identifier NCT01366534:  
363 <https://clinicaltrials.gov/ct2/show/NCT01366534>) compared the ability of two malaria vaccination  
364 regimens to elicit protection against malaria challenge in malaria-naïve recruits from the United  
365 States. The first regimen consisted of three doses of the RTS,S/AS01 vaccine, which combines  
366 a recombinant protein encoding part of the malaria parasite's circumsporozoite (CSP) protein,  
367 the hepatitis B surface antigen, and the AS01 adjuvant. This adjuvant includes the Toll-like  
368 receptor 4 (TLR4) agonist 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the QS-21  
369 saponin<sup>32</sup>. The second regimen was the same as the first except a different vaccine,  
370 Ad35.CS.01, was used for the first immunization. Ad35.CS.01 consists of replication-deficient  
371 adenovirus 35 expressing recombinant CSP. Preimmunization transcriptomics from 45  
372 immunized participants (21 from the first regimen, 24 from the second) were obtained from  
373 PBMCs collected on the day of the first immunization. Participants were challenged with *P.*  
374 *falciparum*-infected mosquitos two weeks following the third immunization.

### 375 Trial 4: CPS

376 The CPS trial<sup>25,26</sup> (ClinicalTrials.gov identifier NCT01218893:  
377 <https://clinicaltrials.gov/ct2/show/NCT01218893>) investigated the influence of dosing level on  
378 the development of protection against malaria challenge when immunizing malaria-naïve  
379 participants using *P. falciparum*-infected mosquito bites obtained under chloroquine prophylaxis.  
380 Participants were recruited in The Netherlands and received three immunizations separated by  
381 4-week intervals. They were challenged 19 weeks after the last immunization by exposure to  
382 bites from five mosquitoes infected with a homologous *P. falciparum* strain. Preimmunization  
383 transcriptomics were obtained from whole blood samples collected one week prior to the first  
384 immunization and were from seven members of the study group immunized with 15 mosquito  
385 bites total.

## 386 Transcriptomic analyses

387 Raw RNA-seq sequencing data were aligned to the hg19 human reference genome using a  
388 previously described pipeline<sup>34</sup>. Briefly, read pairs were adjusted to set base calls with phred  
389 scores less than 5 to "N", and read pairs for which either end had less than 30 unambiguous  
390 base calls were removed. The latter step indirectly removes pairs containing mostly adaptor  
391 sequences. Read pairs were then aligned to the genome using STAR<sup>35</sup> version 2.3.1 and gene  
392 counts were computed using HTSeq<sup>36</sup> version 0.6.0.

393  
394 Differential expression analyses comparing preimmunization sample counts from challenge-  
395 protected trial subjects to non-protected subjects were performed using DESeq2<sup>37</sup> version  
396 1.28.0. Principal Component Analysis (PCA) was used to identify outliers among transcriptomic  
397 samples: If a sample's first or second principal component value was more than three standard

398 deviations from the corresponding principal component's mean, they were excluded from  
399 downstream analyses. One sample from the CPS trial was identified as an outlier based on  
400 PCA. To account for batch effects among trials, we used a DESeq2 design formula that  
401 included a trial term as well as a protected/non-protected classification term. Differential  
402 expression analyses performed on samples from the same trial only included the latter term.  
403

404 Gene Set Enrichment Analysis (GSEA)<sup>27</sup> was performed on gene lists ranked by the DESeq2  
405 Wald test statistic using the fgsea package<sup>38</sup> version 1.14.0 in R. Gene sets used for GSEA  
406 were obtained through the tmod R package<sup>39</sup> and the MSigDB Hallmark gene set<sup>30</sup> download  
407 site (<http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H>). Ingenuity Pathway  
408 Analysis (IPA) content version 62089861 was used to generate all IPA-based results. Receiver  
409 operating characteristic analyses were performed using the pROC package<sup>40</sup> in R. For all  
410 statistical tests, FDR-adjusted *P*-values (Benjamini-Hochberg method<sup>41</sup>) less than 0.05 were  
411 considered significant unless otherwise indicated.

## 412 Data Availability

413 Raw sequencing data for the MAL68 trial is publicly available through Sequence Read Archive  
414 BioProject PRJNA401870. Raw sequencing data for the CPS trial is publicly available at  
415 Sequence Read Archive BioProject PRJNA381264. Data for the IMRAS and BSPZV1 trials will  
416 be available through the ImmPort portal ([immport.org](http://immport.org)).

## 417 Acknowledgements

418 We would like to thank Nana Minkah for helpful discussions regarding preimmunization  
419 correlates, and all volunteers who participated in the clinical trials that were analyzed.

## 420 Author contributions

421 M.L.N. performed all analyses, interpreted findings, and prepared the manuscript. F.J.D.  
422 identified and obtained transcriptomic datasets for analysis, generated counts from sequencing  
423 data, helped guide analyses, and edited the manuscript. Y.D. generated counts from  
424 sequencing data and edited the manuscript. J.D.A. and K.D.S. conceived the study, interpreted  
425 findings, and edited the manuscript.

## 426 Competing Interests

427 The authors declare no competing interests.



## 428 Funding Statement

429 This work was supported by National Institutes of Health grants U19AI128914 (to K.D.S.) and  
430 P41GM109824 (to J.D.A.) as well as Bill & Melinda Gates Foundation grant GHVAP NG-ID18-  
431 Stuart.

## 432 References

- 433 1. Petra, Z. & Nigel, C. Factors that influence the immune response to vaccination. *Clin. Microbiol.*  
434 *Rev.* **32**, e00084-18 (2019).
- 435 2. Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. *npj*  
436 *Vaccines* **5**, 48 (2020).
- 437 3. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or  
438 without a booster dose in infants and children in Africa: final results of a phase 3, individually  
439 randomised, controlled trial. *Lancet* **386**, 31–45 (2015).
- 440 4. Mwakingwe-Omari, A. *et al.* Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic  
441 immunity. *Nature* **595**, 289–294 (2021).
- 442 5. Dattoo, M. S. *et al.* Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M,  
443 with seasonal administration to children in Burkina Faso: a randomised controlled trial. *Lancet*  
444 **397**, 1809–1818 (2021).
- 445 6. HIPC-CHI Signatures Project Team & HIPC-I Consortium. Multicohort analysis reveals baseline  
446 transcriptional predictors of influenza vaccination responses. *Sci. Immunol.* **2**, eaal4656 (2017).
- 447 7. Tsang, J. S. *et al.* Global analyses of human immune variation reveal baseline predictors of  
448 postvaccination responses. *Cell* **157**, 499–513 (2014).
- 449 8. Frasca, D. *et al.* Unique biomarkers for B-cell function predict the serum response to pandemic  
450 H1N1 influenza vaccine. *Int. Immunol.* **24**, 175–182 (2012).
- 451 9. Kennedy, R. B. *et al.* The composition of immune cells serves as a predictor of adaptive immunity  
452 in a cohort of 50- to 74-year-old adults. *Immunology* **148**, 266–275 (2016).
- 453 10. Fourati, S. *et al.* Pre-vaccination inflammation and B-cell signalling predict age-related  
454 hyporesponse to hepatitis B vaccination. *Nat. Commun.* **7**, 10369 (2016).
- 455 11. Bartholomeus, E. *et al.* Transcriptome profiling in blood before and after hepatitis B vaccination  
456 shows significant differences in gene expression between responders and non-responders.  
457 *Vaccine* **36**, 6282–6289 (2018).
- 458 12. Qiu, S. *et al.* Significant transcriptome and cytokine changes in hepatitis B vaccine non-  
459 responders revealed by genome-wide comparative analysis. *Hum. Vaccin. Immunother.* **14**, 1763–  
460 1772 (2018).
- 461 13. Kotliarov, Y. *et al.* Broad immune activation underlies shared set point signatures for vaccine  
462 responsiveness in healthy individuals and disease activity in patients with lupus. *Nat. Med.* **26**,  
463 618–629 (2020).
- 464 14. Ubillos, I. *et al.* Baseline exposure, antibody subclass, and hepatitis B response differentially  
465 affect malaria protective immunity following RTS,S/AS01E vaccination in African children. *BMC*  
466 *Med.* **16**, 197 (2018).
- 467 15. Stanistic, D. I. & McCall, M. B. B. Correlates of malaria vaccine efficacy. *Expert Rev. Vaccines* **20**,  
468 143–161 (2021).
- 469 16. Warimwe, G. M. *et al.* Peripheral blood monocyte-to-lymphocyte ratio at study enrollment  
470 predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data. *BMC*  
471 *Med.* **11**, 184 (2013).
- 472 17. Ishizuka, A. S. *et al.* Protection against malaria at 1 year and immune correlates following PfSPZ  
473 vaccination. *Nat. Med.* **22**, 614–623 (2016).
- 474 18. Sissoko, M. S. *et al.* Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct  
475 venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase  
476 1 trial. *Lancet Infect. Dis.* **17**, 498–509 (2017).
- 477 19. Moncunill, G. *et al.* Antigen-stimulated PBMC transcriptional protective signatures for malaria

- 478 immunization. *Sci. Transl. Med.* **12**, eaay8924 (2020).
- 479 20. Nielsen, C. M. *et al.* RTS,S malaria vaccine efficacy and immunogenicity during *Plasmodium*  
480 *falciparum* challenge is associated with HLA genotype. *Vaccine* **36**, 1637–1642 (2018).
- 481 21. Yap, X. Z., McCall, M. B. B. & Sauerwein, R. W. Fast and fierce versus slow and smooth:  
482 Heterogeneity in immune responses to *Plasmodium* in the controlled human malaria infection  
483 model. *Immunol. Rev.* **293**, 253–269 (2020).
- 484 22. Hickey, B. *et al.* IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-  
485 attenuated *P. falciparum* sporozoites: Impact of immunization parameters on protective efficacy  
486 and generation of a repository of immunologic reagents. *PLoS One* **15**, e0233840 (2020).
- 487 23. Jongo, S. A. *et al.* Safety, immunogenicity, and protective efficacy against controlled human  
488 malaria infection of *Plasmodium falciparum* sporozoite vaccine in Tanzanian adults. *Am. J. Trop.*  
489 *Med. Hyg.* **99**, 338–349 (2018).
- 490 24. Ockenhouse, C. F. *et al.* Ad35.CS.01 - RTS,S/AS01 heterologous prime boost vaccine efficacy  
491 against sporozoite challenge in healthy malaria-naïve adults. *PLoS One* **10**, e0131571 (2015).
- 492 25. Bijker, E. M. *et al.* Cytotoxic markers associate with protection against malaria in human  
493 volunteers immunized with *Plasmodium falciparum* sporozoites. *J. Infect. Dis.* **210**, 1605–1615  
494 (2014).
- 495 26. Tran, T. M. *et al.* Whole-blood transcriptomic signatures induced during immunization by  
496 chloroquine prophylaxis and *Plasmodium falciparum* sporozoites. *Sci. Rep.* **9**, 8386 (2019).
- 497 27. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for  
498 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550 (2005).
- 499 28. Chaussabel, D. *et al.* A modular analysis framework for blood genomics studies: Application to  
500 systemic lupus erythematosus. *Immunity* **29**, 150–164 (2008).
- 501 29. Li, S. *et al.* Molecular signatures of antibody responses derived from a systems biological study of  
502 5 human vaccines. *Nat. Immunol.* **15**, 195–204 (2014).
- 503 30. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark gene set collection. *Cell Syst.* **1**,  
504 417–425 (2015).
- 505 31. Krämer, A., Green, J., Pollard Jr, J. & Tugendreich, S. Causal analysis approaches in Ingenuity  
506 Pathway Analysis. *Bioinformatics* **30**, 523–530 (2014).
- 507 32. Kazmin, D. *et al.* Systems analysis of protective immune responses to RTS,S malaria vaccination in  
508 humans. *Proc. Natl. Acad. Sci.* **114**, 2425–2430 (2017).
- 509 33. Laurens, M. B. RTS,S/AS01 vaccine (Mosquirix™): an overview. *Hum. Vaccin. Immunother.* **16**,  
510 480–489 (2020).
- 511 34. Thompson, E. G. *et al.* Host blood RNA signatures predict the outcome of tuberculosis treatment.  
512 *Tuberculosis (Edinb).* **107**, 48–58 (2017).
- 513 35. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 514 36. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput  
515 sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 516 37. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-  
517 seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 518 38. Korotkevich, G. *et al.* Fast gene set enrichment analysis. *bioRxiv* 60012 (2021).
- 519 39. Weiner 3rd, J. & Domaszewska, T. tmod: an R package for general and multivariate enrichment  
520 analysis. *PeerJ Prepr.* **4**, e2420v1 (2016).
- 521 40. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves.  
522 *BMC Bioinformatics* **12**, 77 (2011).
- 523 41. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful  
524 approach to multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
- 525